Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

NCT00377065 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: raltegravir

Sponsor

Merck Sharp & Dohme LLC